welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Wave Life Sciences Receives US Orphan Drug and Rare Pediatric Disease Designations for WVE-210201
Wave Life Sciences Ltd., a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted both orphan drug designation and rare pediatric disease designation for WVE-210201 for the treatment of Duchenne muscular dystrophy (DMD). The European Commission previously granted orphan drug designation for WVE-210201 in July 2018.
rareRelated
-
Study of DS-5141b in Patients With Duchenne Muscular DystrophyThis is a phase I/II study to evaluate t...
-
The Duchenne RegistryThe Duchenne Registry is an online, pati...
-
This is a Study to Get More Information About Non Ambulatory Boys & Men With Duchenne Muscular DystrophyMany therapeutic trials in DMD exclude n...
-
First Patient Dosed in Phase II Clinical Trial in Duchenne Muscular DystrophyAntisense Therapeutics today announced d...
-
L-citrulline and Metformin in Duchenne’s Muscular DystrophyThe purpose of the study is to show that...
-
A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD)The purpose of this study is to determin...
-
Long-Term Outcomes of Ataluren in Duchenne Muscular DystrophyThis study is a long-term study of atalu...
-
Duchenne UK: DMD Patient and Caregiver Survey Resultshttps://www.youtube.com/watch?v=d2EpSB8R...
-
MDA Releases Duchenne Fact Sheet, Survey Results Pointing to Need for Knowledge of Clinical Trials and Genetic TestsCiting a persistent need for new treatme...
-
There’s No Straight Line in Drug DevelopmentToday’s FDA disapproval of Sarepta’s...
-
Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to strengthen FDA’s expanded access programSince the 1970s, the FDA has helped to f...
